Performance measures in Friedreich ataxia: Potential utility as clinical outcome tools
- 3 March 2005
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 20 (7) , 777-782
- https://doi.org/10.1002/mds.20449
Abstract
Although several neuroprotective agents have been proposed as potential therapies in Friedreich ataxia (FA), clinical trials of their efficacy are limited by a lack of sensitive outcome measures. We assessed whether performance measures (nine‐hole peg test, the timed 25‐foot walk, and low‐contrast letter acuity) provide valid measures of disease status in FA. Scores for each measure correlated significantly with neurologic disability and disease duration. Rank correlations between scores for performance measures were moderate in magnitude, suggesting that the each test captures separate yet related dimensions of neurological function in FA. Linear regression models demonstrated that scores from the nine‐hole peg test and the timed 25‐foot walk (after reciprocal transformation) were predicted by age and triplet repeat length in patients with FA. In addition, comparison of the temporal courses of change for each performance measure demonstrated that scores from the timed 25‐foot walk change early in the course of FA, nine‐hole peg test scores change slowly over the full course of the disorder, and low‐contrast letter acuity scores change in the later stages of the disease. Thus, a composite scale derived from these performance measures may provide the best overall measure for assessing disease progression throughout the illness. © 2005 Movement Disorder SocietyKeywords
This publication has 17 references indexed in Scilit:
- Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trialNeurology, 2003
- Contrast Letter Acuity as a Measure of Visual Dysfunction in Patients with Friedreich AtaxiaJournal of Neuro-Ophthalmology, 2002
- The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trialsMultiple Sclerosis Journal, 2002
- Friedreich AtaxiaArchives of Neurology, 2002
- Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxiaAnnals of Neurology, 2001
- Frataxin point mutations in two patients with Friedreich's ataxia and unusual clinical featuresJournal of Neurology, Neurosurgery & Psychiatry, 2000
- Intrarater and interrater reliability of the MS functional composite outcome measureNeurology, 2000
- Development of a multiple sclerosis functional composite as a clinical trial outcome measureBrain, 1999
- Friedreich's ataxia: Point mutations and clinical presentation of compound heterozygotesAnnals of Neurology, 1999
- International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndromeJournal of the Neurological Sciences, 1997